Table 1 Clinical characteristics of patients with COVID-19
From: Neurological symptoms in COVID-19: a cross-sectional monocentric study of hospitalized patients
|
Total N (%) |
With ARDS N (%) |
Without ARDS N (%) | p-value | |
|---|---|---|---|---|
| Number of patients | 53 | 28 | 25 | |
| Age: years (Median + IQR) | 63 (54–73) | 61.5 (56–68) | 66 (51–77) | .417 |
| Female sex | 21 (39.6) | 10 (35.7) | 11 (44) | .584 |
| Evidence of COVID-19 | ||||
| PCR (respiratory samples) | 53 (100) | 28 (100) | 25 (100) | |
| Chest radiograph / chest computed tomography | 53 (100) | 28 (100) | 25 (100) | |
| Comorbidities | ||||
| Arterial hypertension | 36 (67.9) | 19 (67.9) | 17 (68) | .612 |
| Diabetes mellitus | 15 (28.3) | 5 (17.9) | 10 (40) | .160 |
| Dyslipidaemia | 11 (20.8) | 6 (21.4) | 5 (20) | .585 |
| Smoking | 5 (9.4) | 3 (10.7) | 2 (8) | .414 |
| Ex-smoking | 1 (1.9) | 1 (3.6) | 0 | – |
| History of stroke/TIA | 4 (7.5) | 2 (7.1) | 2 (8) | .509 |
| History of traumatic brain injury | 3 (6.7) | 2 (7.1) | 1 (4) | .543 |
| Depression | 7 (13.2) | 5 (17.9) | 2 (8) | .426 |
| Coronary heart desease | 12 (22.6) | 8 (28.6) | 4 (16) | .076 |
| Atrial fibrillation | 11 (20.8) | 7 (25) | 4 (16) | .509 |
| History of myocardial infarction | 8 (15.1) | 8 (28.6) | 0 | .004 |
| Carotid artery stenosis | 2 (3.8) | 1 (3.6) | 1 (4) | .726 |
| History of cardiovascular surgery (stent/bypass) | 4 (7.5) | 3 (10.7) | 1 (4) | .533 |
| Medication | ||||
| Antihypertensive drug | 36 (67.9) | 16 (57.1) | 20 (80) | .562 |
| Anticoagulant | 21 (39.6) | 18 (64.3) | 3 (12) | .0001 |
| Antidepressant | 3 (6.7) | 3 (10.7) | 0 | .335 |
| Anticonvulsant | 2 (3.8) | 0 | 2 (8) | .466 |
| Anti-psychotic | 5 (9.4) | 5 (17.9) | 0 | .101 |
| Anti-parkinson | 2 (3.8) | 1 (3.6) | 1 (4) | .934 |
| Statins | 6 (11.3) | 2 (7.1) | 4 (16) | .309 |
| Immunosuppressant | 8 (15.1) | 5 (17.9) | 3 (12) | .513 |
| Other (Ibuprofen, Tilidine, L-Thyroxine, Pantoprazole, Salbutamol) | 16 (30.2) | 11 (39.3) | 5 (20) | .126 |